Only ASX-listed Healthcare Company Developing CAR-T Programs- PTX Collaborates With Peter MacCallum Cancer Centre

On 14 August 2020, Prescient stock zoomed up by 6.667% to A$0.064 at AEST 2:12 PM after the Company reported a research collaboration with the world-class cell therapy institute Peter MacCallum Cancer Centre (Peter Mac) for developing innovative cell therapy technologies, including CAR-T technologies (Press release, Prescient Therapeutics, AUG 14, 2020, View Source;utm_medium=rss&utm_campaign=only-asx-listed-healthcare-company-developing-car-t-programs-ptx-collaborates-with-peter-maccallum-cancer-centre [SID1234565506]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of this research agreement, Prescient will own the IP (intellectual property) generated from the research program being led by Professor Phil Darcy of Peter Mac.

Melbourne-based Peter MacCallum Cancer Centre is an internationally recognised research and clinical leader in developing new therapies for cancer.

This is the second addition to the Cell Therapy Enhancement (CTE) Programs of Prescient Therapeutics. Prescient is already working with Carina Biotech and University of Adelaide on other CTE approaches.

Complementing the CTE programs, Prescient is also developing next-generation CAR-T therapies with its OmniCAR platform, following it announcement in late May 2020 that Prescient obtained key licenses from the University of Pennsylvania and Oxford University.

To Know More, Do Read: Impressive! Prescient Obtains Key Licenses for Next-Generation Immunotherapy Platform

Currently, Prescient Therapeutics is conducting a Share Purchase Plan (SPP) at 5.5c which closes on 20 August 2020 at AEST 5:00 PM. Click here to request personalised SPP forms.

Cell Therapy Enhancements Programs of Prescient

CAR-T is a cellular therapy that reprograms the immune cells of a cancer patient to identify and destroy cancer.

The research program, being undertaken in Professor Darcy’s laboratory at Melbourne-based Peter Mac, is an important addition to the Cell Therapy Enhancements (CTE) programs in the pipeline of Prescient.

On the same lines as the Cell Therapy Enhancements program that is underway with Carina Biotech, this research program aims to produce technologies complementing current CAR-T approaches.

The objective of Prescient’s CTE program is to develop efficacy as well as efficiency improvements that are relevant to 3rd parties in the cell therapy field (called CAR-T), which may incorporate these into their own programs under license.

Also Read: Get Acquainted with Prescient Therapeutics’ Next Generation Immunotherapy Platform

It is noteworthy to mention that Prescient will retain its previously built intellectual property and look to extend this portfolio by collaborating with world-renowned cancer centre Peter Mac.

Prescient Therapeutics CEO Steven Yatomi-Clarke stated that PTX is the only ASX-listed healthcare company developing CAR-T programs, and this is an important strategic initiative to complement programs of the Company in Cell Therapy Enhancements.

He also added-

Bottomline

Prescient has been progressing well in its cell therapy platform by obtaining two major licenses for developing innovative universal CAR Platform and now by collaborating with world-renowned Institute ‘Peter MacCallum Cancer Centre’. These developments drive Prescient to create innovative cell therapies for treating challenging cancers having unmet medical need.

These events demonstrate that Prescient Therapeutics is on a growth track backed by strong management in the most modern arena of cancer therapy.

Seneca Biopharma Reports 2020 Second Quarter Results

On August 14, 2020 Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, reported its financial results for the quarter ended June 30, 2020 (Press release, Neuralstem, AUG 14, 2020, View Source [SID1234563654]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Business Highlights for 2020 to date.

During the First Half of 2020, the Company achieved the following business milestones:

Completed offerings resulting in net proceeds of over $14.8 million.
Continued progress on both the Company’s out-licensing effort to partner NSI-566 and NSI-189 programs and initiative to in-license or acquire novel therapeutics.
Appointed of Matthew W. Kalnik, Ph.D. as President and Chief Operating Officer and Dane R. Saglio as Chief Financial Officer.
Affirmed guidance that data readout from the Company’s non-GCP Phase II trial evaluating NSI-566, for the treatment of chronic ischemic stroke, is expected during the second half of 2020.
Announced that as a result of feedback received from the FDA, Seneca believes that the existing Phase 1 and 2 trial results support moving into a Phase 3 clinical study for ALS.
Completion of the Company’s stem cell manufacturing facility in Suzhou, China which will be used to manufacture NSI-566 for clinical trials within China.
Financial Results for the Quarter Ended June 30, 2020

Cash Position and Liquidity: At June 30, 2020, cash was approximately $15.8 million as compared to approximately $10 million at March 31, 2020. The increase in cash is attributed to the May 2020 warrant exercises and registered direct offering.

Operating Loss: Operating loss for the quarter ended June 30, 2020 was $1.9 million compared to a loss of $1.9 million for the comparable 2019 period. For the six-month period ended June 30, 2020, the operating loss was $3.9 million versus $4.4 million for the six months ended June 30, 2019. The decrease in operating loss for 2020 was primarily due to a decrease in R&D expenses as we continue to wind down the clinical programs. This decrease was partially offset by an increase in G&A expenses which reflects an enhanced management structure to support corporate objectives as compared to the same period of 2019.

Net Loss: Net loss for the quarter ended June 30, 2020 was $2.0 million, or $0.15 per share, compared to a loss of $1.4 million, or $1.45 per share on a post-reverse stock-split basis, for the same period in 2019. For the 2020 six-month period the net loss was $9.5 million, or $0.92 per share versus a net loss of $4.6 million, or $4.78 per share for the same period in 2019. The 2020 increase in net loss was primarily attributed to a non-cash expense of $5.6 million related to the January 2020 warrant inducement transaction.

Prescient partners with global cancer heavyweight to develop new treatments

On August 14, 2020 Prescient Therapeutics (ASX:PTX) reported that it has formed a cancer research partnership with the world-renowned Peter MacCallum Cancer Centre, ‘Peter Mac’, a leader in new clinical treatments for cancer to develop CAR-T cell therapy technologies (Press release, Prescient Therapeutics, AUG 14, 2020, View Source;utm_medium=rss&utm_campaign=prescient-partners-with-global-cancer-heavyweight-to-develop-new-treatments [SID1234565488]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The research program is being led by Professor Phil Darcy, head of cancer immunotherapy at Peter Mac’s Melbourne laboratory and will seek to produce technologies that can complement existing CAR-T cancer treatment approaches.

Prescient is the only ASX company that is developing CAR-T programs and it will own the intellectual property rights stemming from the research program.

The company’s CAR-T cancer treatment reprograms the Chimeric Antigen Receptors (CAR) on the outside of T-Cells to enable them to better target and eradicate cancer cells within patients.

Prescient Therapeutics chief executive Steven Yatomi-Clarke said the company’s research partnership with Peter Mac would greatly enhance efforts to advance new cancer treatments that would benefit patients.

"We look forward to working closely with Peter Mac as we employ our knowledge of targeted therapies and growing standing in cellular therapies to generate technologies that will be relevant for the CAR-T field," Yatomi-Clarke said.

Peter Mac research will advance PTX’s treatments
The research program at Peter Mac is an important addition to the Cell Therapy Enhancements (CTE) programs in Prescient’s treatments pipeline.

Prescient develops personalised medical approaches to cancer including targeted and cellular therapies such as its OmniCar immune receptor platform, an advanced version of CAR-T cancer treatment.

The company’s CTE programs aim to create efficacy and efficiency enhancements that are relevant to third parties in the cell therapy field, namely CAR-T, which may incorporate these into their own programs under licence.

Professor Darcy said the research with Prescient aimed to reprogram the microenvironment of cancer tumours to achieve better results with the CAR-T therapy.

"CAR-T therapy has shown strong therapeutic activity in certain haematological malignancies, however, the effects in solid cancers have been poor to date," he said.

"The approach we are exploring with Prescient may reprogram the tumour microenvironment that results in significantly enhancing CAR-T cell anti-tumour activity."

Boosting the coffers by $6.5m
Prescient has launched a capital raising for $6.5m via a share purchase plan to fund the expansion of its line of cancer treatments, including clinical trials of its PTX 100 and 200 products, and OmniCAR platform.

The SPP share issue is priced at 5.5c, a 15 per cent discount to its volume-weighted average share price prior to the SPP announcement, and it closes August 17.

Myriad Genetics Announces Inducement Awards

On August 14, 2020 Myriad Genetics, Inc. (NASDAQ: MYGN, "Myriad" or the "Company"), a global leader in molecular diagnostics and precision medicine, reported that in connection with the previously announced appointment of Paul J. Diaz as President and Chief Executive Officer of the Company, effective yesterday, August 13, 2020, the Company’s Board of Directors authorized the grant to Mr. Diaz of (i) a restricted stock unit award for 298,954 shares of the Company’s common stock, effective as of the first day of his employment (the "RSUs"); (ii) a performance stock unit award for 298,954 shares of the Company’s common stock, to be effective within a reasonable period of time following his first day of employment (the "PSUs"); (iii) a time-based non-qualified stock option for the purchase of 342,040 shares of the Company’s common stock, effective as of the first day of his employment (the "Time-Based Options"); and (iv) a performance-based non-qualified stock option for the purchase of 339,088 shares of the Company’s common stock, effective as of the first day of his employment (the "Performance-Based Options" and together with the RSUs, PSUs and Time-Based Options, the "Inducement Awards") (Press release, Myriad Genetics, AUG 14, 2020, View Source [SID1234563655]). The Inducement Awards are inducements material to Mr. Diaz’s entering into employment with the Company in accordance with Nasdaq listing Rule 5635(c)(4).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Time-Based Options and Performance-Based Options have an exercise price of $13.38 per share, the fair market value of the Company’s common stock on the date of grant. The Time-Based Options will vest as to 25% of the shares on each of the first four anniversaries of Mr. Diaz’s employment. The shares subject to the Performance-Based Options become eligible to vest upon achievement of certain stock price targets and shall vest as to one-fifth (1/5) of the shares subject to the Performance-Based Options upon achievement of each of five stock price targets, provided that no portion of the Performance-Based Options may vest earlier than the first anniversary of Mr. Diaz’s employment. The Time-Based Options and Performance-Based Options each have seven-year terms and are subject to the terms and conditions of their respective stock option agreements.

The RSUs will vest as to 50% of the shares on the first anniversary of Mr. Diaz’s employment with the remainder vesting in equal instalments on each of the second, third and fourth anniversaries of Mr. Diaz’s employment. The shares subject to the PSUs become eligible to vest upon achievement of certain performance targets for the fiscal year ending June 30, 2021. To the extent that the performance targets have been met, the PSUs will vest as to 25% of the shares on the date the performance targets are determined to have been met, with the remainder vesting in equal instalments on each of the second, third and fourth anniversaries of Mr. Diaz’s employment. The RSUs and PSUs are subject to the terms and conditions of their respective restricted stock unit agreements.

RAPT Therapeutics Reports Second Quarter 2020 Financial Results

On August 14, 2020 RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, reported financial results for the second quarter ended June 30, 2020 and provided an update on recent operational and business progress (Press release, RAPT Therapeutics, AUG 14, 2020, View Source [SID1234563658]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We remain on track to report initial results from our Phase 1/2 trial of FLX475 later this year and to report results from our Phase 1b study of RPT193 in patients with atopic dermatitis by year end," said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics. "We are pleased with the progress we are making in moving our programs forward and adapting our organization in the face of the COVID-19 pandemic."

Financial Results for the Second Quarter and Six Months Ended June 30, 2020

Second Quarter Ended June 30, 2020
Net loss for the second quarter of 2020 was $12.4 million, compared to $10.6 million for the second quarter of 2019.

Research and development expenses for the second quarter of 2020 were $11.0 million, compared to $8.3 million for the same period in 2019 due to increased clinical costs for FLX475 and RPT193 as well as increased personnel costs associated with these studies and stock-based compensation expenses, offset by a decrease in lab supplies used for preclinical research.

General and administrative expenses for the second quarter of 2020 were $2.8 million, compared to $2.7 million for the same period of 2019. The slight increase was primarily due to an increase in stock-based compensation expense and costs associated with our public company status, offset by a decrease in professional fees.

Six Months Ended June 30, 2020
Net loss for the six months ended June 30, 2020 was $25.5 million, compared to $19.8 million for the same period in 2019.

Research and development expenses for the six months ended June 30, 2020 were $21.7 million, compared to $16.1 million for the same period in 2019. The increase was primarily due to increases in costs relating to the clinical development of FLX475 and RPT193 and increased preclinical program costs as well as increased stock-based compensation and personnel expenses, offset by decreases in costs relating to lab supplies used for preclinical research.

General and administrative expenses for the six months ended June 30, 2020 were $6.1 million, compared to $4.4 million for the same period of 2019. The increase in general and administrative expenses was primarily due to increased stock-based compensation expense as well as costs associated with our public company status, offset by a decrease in travel and personnel costs.

As of June 30, 2020, we had cash and cash equivalents and marketable securities of $133.0 million.